
Trump’s trade war just got personal for Big Tech. The US has moved forward with fresh investigations that could lead to tariffs on semiconductors and pharmaceuticals — and Nvidia is already paying the price. The AI giant will take a massive $5.5 billion charge as its key H20 chip is blocked from China. With chipmakers like AMD and Broadcom also sliding, this could be the start of a major tech showdown.
🧠 Here’s What’s Going Down:
-
The Trump administration is ramping up its trade crackdown — launching official probes into:
-
Semiconductors and chip equipment
-
Pharmaceuticals and drug ingredients
-
-
These investigations are the first step toward new import tariffs, citing national security risks.
-
Targets include all chips — from basic to advanced AI processors — and even drug ingredients that go into lifesaving medicines.
💥 New Bombshell: Nvidia Takes a $5.5 Billion Hit
-
Nvidia shares tanked 6% after announcing it will write down $5.5 billion due to new US rules banning exports of its H20 AI chip to China.
-
The H20 chip, key to China’s AI surge, was built to avoid previous export controls but is now caught in the crossfire.
-
US officials say H20’s high-speed capabilities could help Chinese supercomputers, raising national security flags.
-
No export licenses are currently approved — and the ban is indefinite.
🔍 What’s the H20?
-
Nvidia’s most advanced AI chip legally sellable in China
-
Optimized for AI inference (real-time AI results)
-
Used by Chinese giants like Tencent, Alibaba, ByteDance
-
Now under intense scrutiny from Washington
🔻 AI Chip Sector Gets Slammed
-
After Nvidia’s bombshell:
-
AMD shares fell 7%
-
Broadcom dropped nearly 4%
-
-
Analysts warn of a wider AI supply chain shock, especially with chips used in cloud computing, mobile devices, and smart infrastructure.
💊 On the Pharma Front…
-
Trump’s other target: drug imports
-
The US probe includes all finished medicines and active ingredients
-
Industry giants like Merck, Eli Lilly, and Novartis face tough decisions: raise prices or slash R&D
-
Novartis recently pledged $23B in US investments, but experts say that won’t offset damage if tariffs hit
🧨 The Bigger Picture
-
The new probes come under Section 232, which means tariffs could roll out fast
-
If implemented, tariffs could:
-
Raise medicine and electronics prices
-
Disrupt global supply chains
-
Slow down AI innovation
-
Hit tech stock valuations
-
-
Drugmakers may scale back research, hurting innovation in the long run




